Business Context and Reporting Period
This Form 8-K filing by RXi Pharmaceuticals Corporation (trading symbol: RXII) reports on events occurring on April 14, 2016. The primary event is the approval and implementation of a reverse stock split of the company's common stock following a Special Meeting of Stockholders.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
- Pre-Split Outstanding Shares: Approximately 65.3 million.
- Post-Split Outstanding Shares: Approximately 6.5 million.
- Reverse Stock Split Ratio: 1-for-10.
- Fractional Share Cash Payment Rate: $2.71 per fractional share (based on the average closing price of the ten trading days ending April 14, 2016).
Material Changes Versus Prior Period
The material change reported is the reduction of issued and outstanding common stock by a factor of ten. This change was approved by stockholders and filed with the Delaware Secretary of State on April 14, 2016. The split is effective as of 12:01 a.m. Eastern Time on April 18, 2016. Consequently, the number of authorized shares available for issuance relative to outstanding shares has increased, while the par value and voting rights of the common stock remain unchanged.
Guidance, Outlook, and Management Commentary
The filing does not provide financial guidance, future outlook, or management commentary regarding operational performance. The document details the mechanics of the reverse stock split, including:
- Adjustments to the per-share exercise price and number of shares for outstanding stock options, warrants, and purchase rights.
- Proportionate reduction in shares authorized under equity incentive and employee stock purchase plans.
- Issuance of post-split shares via Computershare's Direct Registration System (DRS).
- Assignment of a new CUSIP number (74979C501) effective post-split.
Important Facts for Investor Verification
- Verify the effective date of the reverse stock split (April 18, 2016) and the new trading symbol (RXII).
- Confirm the new CUSIP number (74979C501) for post-split trading.
- Check instructions from brokers or Computershare regarding the exchange of pre-split certificates and the handling of fractional shares (cash payment at $2.71).
- Review the impact of the split on existing equity awards (options, warrants) to ensure exercise prices and share counts have been adjusted proportionately.
- Note that the filing does not provide updated financial statements; investors should refer to the most recent 10-K or 10-Q for financial health.